We have the technology to save thousands of lives, experts say, and we must start using it now
Australia is on the brink of a healthcare revolution driven by DNA science that will save lives and prevent disease – but top ...
STAT11h
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
STAT13h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
3 Ways The New Administration Could Speed The Path To New Medicines
U.S. policies that fix the IRA, strengthen patents, and incentivize antimicrobial research could help hasten new medicines ...
Institutional Investor1d
Casdin Capital Leads a Strong Month for Biopharma Funds
The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...
Irish Independent on MSN1d
“If not now, why?” – How Ireland has a golden opportunity to be at the forefront of cell therapy
Ireland has a golden opportunity to build on existing scientific, biomanufacturing, and clinical strengths and create a unique ecosystem to rival other, more established centres in Europe. The ...
Promising Outlook for Revolution Medicines: Buy Rating Backed by Strong RAS ON Inhibitor Progress and Financial Stability
In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research ...
Revolution Medicines (NASDAQ:RVMD) Given New $68.00 Price Target at Needham & Company LLC
Revolution Medicines (NASDAQ:RVMD – Free Report) had its target price increased by Needham & Company LLC from $61.00 to $68.00 in a report issued on Thursday morning,Benzinga reports. They currently ...
Stifel Nicolaus Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a ...
bovnews5d
Needham Issues Buy Rating for Revolution Medicines Inc (RVMD) Stock
On Friday, Revolution Medicines Inc (RVMD) stock saw a modest uptick, ending the day at $60.44 which represents a slight increase of $1.34 or 2.27% from the prior close of $59.1. The stock opened at ...
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...